Last reviewed · How we verify

Kashiv BioSciences, LLC — Portfolio Competitive Intelligence Brief

Kashiv BioSciences, LLC pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
FYLNETRA PEGFILGRASTIM-PBBK marketed Leukocyte Growth Factor [EPC] specific cell surface receptors Other
RELEUKO FILGRASTIM-AYOW marketed Leukocyte Growth Factor [EPC] Other
Xolair Prefilled Syringe Xolair Prefilled Syringe phase 3 Monoclonal antibody (anti-IgE) Immunoglobulin E (IgE) Immunology / Allergy

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Amgen · 1 shared drug class
  3. Berlex Labs · 1 shared drug class
  4. EVIVE BIOTECHNOLOGY · 1 shared drug class
  5. FRESENIUS KABI USA · 1 shared drug class
  6. LUPIN LTD · 1 shared drug class
  7. MYLAN GMBH · 1 shared drug class
  8. SANDOZ INC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kashiv BioSciences, LLC:

Cite this brief

Drug Landscape (2026). Kashiv BioSciences, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kashiv-biosciences-llc. Accessed 2026-05-16.

Related